Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Tesamorelin

GHRH Analog (Egrifta)

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

grade 4 applies only to the narrow FDA-approved indication, reduction of excess visceral abdominal fat in HIV-associated lipodystrophy, supported by two pivotal 26-week phase 3 placebo-controlled RCTs (Falutz et al., NEJM 2007, and the confirmatory multicenter trial) totaling roughly 800 randomized patients, with a 52-week extension (Falutz et al., JAIDS 2010) showing durability and rapid regain of visceral fat on discontinuation. This is strong multi-RCT evidence for one indication, not the grade 5 overwhelming-consensus tier; the off-label anti-aging, growth-hormone-optimization and bodybuilding use is unapproved and rests on extrapolation rather than its own RCT base, so that halo is honestly grade 1.

FDA
FDA approved November 10, 2010 (Egrifta) for excess visceral abdominal fat in HIV-associated lipodystrophy; F8 formulation approved as Egrifta WR. No approval for anti-aging, GH optimization, or body recomposition in healthy adults.
WADA
Prohibited at all times (S2, peptide hormones/growth factors/GHRH analogs)

Reference only. Not medical advice.

What can go wrong

Raises serum IGF-1 (long-term effects unknown, monitor and consider discontinuation if persistently elevated); associated with glucose intolerance; contraindicated with hypothalamic-pituitary axis disruption or active malignancy; injection-site reactions; effect reverses on stopping; costly; WADA-prohibited; anti-aging and bodybuilding use is off-label and unapproved.

Talk to a clinician before taking this, particularly if you have any history of cancer. The Atlas can tell you what has been studied about Tesamorelin. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

The only FDA-approved GHRH analog, cleared for HIV-associated lipodystrophy. Off-label use for visceral fat reduction and growth-hormone optimization in healthy adults has grown substantially.

The only FDA-approved GHRH analog. Reduces visceral fat. Widely used off-label.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • HIV lipodystrophy (FDA approved)
  • Visceral fat / body recomposition (off-label)
  • GH optimization
HIV-associated lipodystrophy (Egrifta)
FDA-approved in 2010 to reduce excess visceral abdominal fat in adults with HIV on antiretroviral therapy. It is the only FDA-approved GHRH analog and one of very few approved peptides for any fat-reduction use.

How it works

Tesamorelin is a growth-hormone-releasing hormone analog: it tells the pituitary to release the body's own growth hormone in natural pulses, which raises IGF-1 and, distinctively, shifts fat metabolism toward burning visceral fat, the deep fat around the organs, and reducing fat in the liver. Because it works through the normal GHRH pathway, it preserves the brain's feedback control rather than overriding it the way injected growth hormone does. That targeted effect on visceral and liver fat, rather than general weight, is what sets it apart and what earned it approval.

Tesamorelin is a stabilized synthetic version of the full 44-amino-acid human GHRH, with a trans-3-hexenoic acid group added at one end to resist the enzyme that would otherwise break it down quickly. Developed by Theratechnologies and sold as Egrifta, then the reformulated Egrifta SV and a weekly-reconstitution Egrifta WR, it is the only growth-hormone-releasing analog to reach full FDA approval. Its full-length, pulsatility-preserving design is part of why it is viewed as the more physiological and better-validated member of the GHRH-peptide family.

Type
GHRH analog (full 1-44)
Half-life
~26 minutes
Dose
2 mg daily (or weekly WR)
Brand
Egrifta / Egrifta SV
Approved for
HIV lipodystrophy
Maker
Theratechnologies

Approved For One Thing, Used For Another

Tesamorelin is the legitimate one in a family full of gray-market imitators, and that is exactly what gets stretched. Its FDA approval is narrow and specific: reducing excess visceral fat in adults with HIV-associated lipodystrophy. Yet the fast-growing use, with US search interest up roughly 50% in six months, is off-label, for general belly fat, anti-aging and fatty liver disease in people without HIV. The non-HIV evidence is real but small, not the large trials that support a general-obesity claim, and the branded drug is very expensive, which pushes people toward cheaper compounded versions. Two more facts the enthusiasm skips: the effects reverse within months of stopping, so it behaves like an ongoing treatment rather than a fix, and it carries the growth-hormone downsides of joint pain, fluid retention and higher blood sugar, plus a hard contraindication in anyone with cancer.

Safety in detail

The FDA label contraindicates tesamorelin in patients with disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or trauma) and in active malignancy; preexisting malignancy should be inactive and its treatment complete before starting. Because tesamorelin stimulates growth hormone and raises IGF-1, IGF-1 and glucose status should be evaluated before and during therapy. Benefits are indication-specific to HIV lipodystrophy and were not established for otherwise healthy adults.

  • The most common effects are joint pain (arthralgia), peripheral swelling (edema) and mild increases in blood sugar, all consistent with raising growth hormone.
  • It is contraindicated in anyone with active cancer of any type, given growth hormone’s role in cell proliferation, and in pregnancy and breastfeeding.
  • IGF-1 levels are monitored during treatment to avoid excessive growth-hormone effect.
  • Injection-site reactions are common with the daily subcutaneous dose.
  • Benefits reverse within months of stopping, so continuous use is required to maintain them.
  • It is prohibited in sport year-round under the World Anti-Doping Code, though it is not a scheduled controlled substance.
  • It is allergenic to people sensitive to mannitol, an inactive ingredient.

Children and teenagers

Tesamorelin is approved only in HIV-positive adults and has no pediatric indication. Growth-hormone-axis treatment in children belongs solely with a pediatric endocrinologist using approved growth hormone for a diagnosed deficiency; notably, the related but distinct peptide sermorelin once held a pediatric growth-deficiency approval, but tesamorelin does not. There is no role for off-label or anti-aging tesamorelin use in anyone under 18, and manipulating growth hormone in a developing child outside specialist care would be inappropriate.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Tesamorelin has a genuine pharmaceutical owner: Theratechnologies, which markets the branded Egrifta line at a high specialty-drug price, with the HIV-lipodystrophy indication as its anchor. Around that sits a second economy: compounding pharmacies preparing much cheaper tesamorelin, and anti-aging and metabolic clinics building off-label visceral-fat and longevity programs around it. So unlike the purely gray-market GH peptides, tesamorelin’s money is split between a regulated brand and a large, lower-cost off-label and compounded market that its price actively encourages.

How we got here

Tesamorelin was developed by Theratechnologies as a synthetic analog of human growth-hormone-releasing hormone (GHRH), created by attaching a trans-3-hexenoic acid group to the amino terminus of GHRH(1-44) to resist enzymatic degradation. Originally designated TH9507, it received FDA approval in November 2010 under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. Later reformulations were marketed as Egrifta SV and Egrifta WR.

Tesamorelin was developed by Theratechnologies specifically for HIV-associated lipodystrophy, a stigmatizing redistribution of body fat caused by older HIV therapies. Two pivotal Phase 3 trials, published in the New England Journal of Medicine in 2007, showed meaningful visceral-fat reduction, and the FDA approved Egrifta in November 2010, making tesamorelin the first and only approved GHRH analog. A reformulated Egrifta SV followed in 2019 and a weekly-reconstitution version later. Over the 2010s and 2020s, interest expanded well beyond HIV into off-label visceral-fat reduction, fatty-liver disease and anti-aging, supported by smaller academic studies and amplified by the broader peptide-wellness wave.

  1. 2000sTheratechnologies develops tesamorelin for HIV-associated lipodystrophy.
  2. 2007Pivotal Phase 3 trials (NEJM) show 15 to 18% visceral-fat reduction.
  3. Nov 2010FDA approves Egrifta, the first and only approved GHRH analog.
  4. 2019Reformulated Egrifta SV approved for the same indication.
  5. 2010s-2020sOff-label use for visceral fat, fatty liver and anti-aging grows rapidly.
  6. 2025New formulations (weekly-reconstitution and F8) approved; search interest climbs.

The numbers behind the grade

Approved
Egrifta, 2010
Type
GHRH (full 1-44)
Visceral fat
-15 to 18%
Approved for
HIV lipodystrophy
WADA
Prohibited
Maker
Theratechnologies

The people taking it

Rising quickly in visibility, with US search interest up about 50% in six months, and widely described as the FDA-approved peptide for belly fat. It is the credibility anchor of the GHRH-peptide category, even as most of its growth is off-label.

Tesamorelin’s approved population is specific: adults with HIV-associated lipodystrophy. Its off-label population is broad and growing, skewing toward middle-aged and older adults seeking visceral-fat reduction, metabolic improvement, fatty-liver help or anti-aging benefit, often through clinics. The sharp recent rise in search interest reflects that off-label crowd more than the HIV indication. Access is shaped heavily by cost, since the brand is expensive and the compounded route is what most off-label users actually use.

Approved and prescribed to reduce visceral abdominal fat in adults with HIV-associated lipodystrophy, and used widely off-label for general visceral fat, fatty-liver disease, body composition and anti-aging. Acts through the natural growth-hormone pathway. Prohibited in sport year-round.

Set against the alternatives

Tesamorelin is best understood against its own family. Compared with CJC-1295, the popular gray-market GHRH analog, tesamorelin is FDA-approved, backed by Phase 3 data, and preserves the natural pulsing of growth hormone, whereas CJC-1295 with DAC produces a flatter, sustained elevation and has no approval. Compared with sermorelin, a shorter GHRH fragment once approved for pediatric growth-hormone deficiency and now sold cheaply through compounding, tesamorelin is the full-length, better-studied molecule but far more expensive as a brand. And compared with injecting growth hormone directly, tesamorelin keeps the body’s feedback loop intact rather than overriding it. Within this family it is the evidence-based option; its main barrier is cost, which is precisely what drives people to the unapproved alternatives.

What we do not know

  • Whether the off-label use for general belly fat, fatty liver and anti-aging is justified by the relatively small non-HIV evidence.
  • Whether tesamorelin earns a broader approval, particularly for fatty-liver disease (NAFLD/MASLD).
  • What the long-term risks of sustained growth-hormone elevation are in otherwise healthy off-label users.
  • How the high brand cost and reliance on compounding affect safety and consistency.
  • How it truly compares with newer metabolic options for visceral fat.

What could change

Fatty-liver diseaseNAFLD/MASLD is the most plausible next formal indication, given the documented liver-fat effect.CognitionEarly signals in memory and executive function keep cognitive use under study.Convenience formulationsWeekly-reconstitution and newer formulations aim to simplify the daily regimen.The off-label visceral-fat marketContinued growth of compounded, clinic-based use beyond the HIV indication.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

The branded route is a prescription for Egrifta or Egrifta SV, primarily for the HIV indication. The off-label route is a clinician’s prescription filled as compounded tesamorelin by a licensed 503A or 503B pharmacy, which is how most non-HIV visceral-fat and anti-aging use is supplied. A small gray-market vendor presence exists but is not the main channel.

Branded Egrifta SV is a high-cost specialty drug, often running into the thousands of dollars per month, which makes long-term off-label use impractical at brand pricing. Compounded tesamorelin is dramatically cheaper and is what most off-label users rely on. As always, the lower-cost compounded route carries more variability than the branded product, though it is more controlled than a research vial.

The branded product comes from Theratechnologies under full pharmaceutical controls. Compounded tesamorelin comes from licensed US pharmacies with meaningful oversight, more than a research vial though less standardized than the brand. This relatively legitimate supply picture distinguishes tesamorelin from the gray-market GH peptides it is often grouped with.

Theratechnologies (branded, regulated)Egrifta, Egrifta SV and the weekly Egrifta WR are manufactured as FDA-approved products under cGMP and dispensed by prescription, a fully traceable chain.Compounding pharmaciesLicensed 503A and 503B pharmacies prepare much cheaper compounded tesamorelin, the main route for off-label visceral-fat and anti-aging use.Clinic channelAnti-aging and metabolic clinics bridge prescribers and compounders for off-label programs.Research vendorsA smaller gray-market vendor presence exists, but tesamorelin’s real off-label supply runs through compounding rather than research vials.

At a glance

Approval
Egrifta, HIV lipodystrophy
Effect
Visceral fat reduction
Class
GHRH analog
Off-label
Body recomposition

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Tesamorelin.

Nothing outstanding on this one.

Sources

The studies that matter

  • LIPO-010 and LIPO-011 (Falutz et al, NEJM)2007

    Two pivotal Phase 3 trials in more than 800 patients with HIV-associated lipodystrophy showed a 15 to 18% reduction in visceral fat over 26 weeks, improved lipids and better body-image scores, the basis for FDA approval.

  • Cognition substudy (Marquine et al)2014

    Suggested improvements in verbal memory and executive function in HIV-positive patients, an early signal behind off-label cognitive interest.

  • Non-HIV visceral fat and fatty-liver studies2010s-2020s

    Academic studies (notably from Massachusetts General) found reductions in visceral and liver fat in non-HIV populations, encouraging but too small to support a general approval.

  • General-obesity efficacynot established

    No large trial supports tesamorelin for ordinary weight loss or general abdominal obesity; that use is off-label extrapolation.